Invest in the weight loss drug revolution and beyond
$HRTS ETF
Learn more
Yuri Khodjamirian, CFA

Yuri Khodjamirian, CFA

Recent Posts

Top Biotech Deal Therapeutic Areas: Oncology, Neurology, and Cardiometabolic

According to IQVIA, if we include partnerships/collaborations, in 2023 there were 31 deals above the value of $2bn. Three major areas are emerging as...

4 Reasons why M&A is an important source of return in biotech investing

M&A is picking up in the biopharma space. Seven names owned across our life science funds, especially in oncology, have received takeover offers. In...

Investing In The Fight Against Obesity: The Case For Active ETFs

Weight-loss drugs have seen tremendous growth since the approval in mid-2021 of Wegovy (the brand name of semaglutide, also found in Ozempic, and...

Q1 2024 CIO Investor Update

Quarterly Market Commentary Markets continued their rally in Q1 2024, clocking in +10.6% for the S&P 500 and 9.0% for MSCI World. Our guiding...

Generating Investment Ideas

There are 24,000 listed equities in the world that meet the minimum inclusion criteria for our ETFs1. So how do we go from that to a final portfolio?...

Q4 2023 CIO Investor Update

Quarterly Market Commentary The calendar often marks what are somewhat arbitrary posts along an investor’s journey and the year just gone as a case...

Tema's Active Investment Process

Tema’s active investment process consists of four key steps Each process step is either fundamental (human driven) and/or systematic (rules...

Artificial Intelligence (AI) and Incumbent Data Moats

Artificial intelligence in the form of natural language models burst onto the scene with the launch of Chat GPT from Open AI, which gained one...

Valuation

Once we establish that the company under analysis has solid foundations and meets pillar one (operating base) and pillar two (balance sheet and cash...

2023 Rewind: 26 Key Insights from Last Year

From technological leaps to socio-economic shifts, we unwind the key highlights of this year that will define the landscape of 2024 and the years...

Security Selection

When it comes to alpha generation, one thing matters most according to Institutional Investor1 – picking the right stocks.

Tema's Edge

Many active managers shy away from explicitly discussing edge in their investment process. Others give convoluted or complicated answers. We firmly...

Risk Management

If a person jumps out of a plane with a single parachute, their chances of it failing are 0.01%. If a person jumps out of a plane with two parachutes...

Tema ETFs Portfolio Construction Process

One of the surprising findings of a large academic study of 750 successful managers1 relates to portfolio construction. While this universe of...

Tema Trends: Exploring Monopoly, Luxury ETFs and Reshoring Insights

In this edition of Tema Trends we: Ask ourselves whether the rapidly evolving technology sector has the potential to create enduring...

Operating Base

What does it mean to say a company has a good operating base? The concept, though not something that is used often in financial and business worlds,...

CIO Reflections: Q2 2023

On May 11th , 2023 , Tema launched its first three funds.

Balance Sheet and Cash Flow

Investing in the stock market can often be boiled down to understanding two seemingly simple, yet incredibly powerful, financial metrics – the...

Monopolies: how Tema seeks to identify and invest in moat-like businesses

Many equity investors now know that quality and competitive advantage (moats1) matters. However, identifying firms that can sustain these for the...

No results found